New US missile, untested in combat, used for striking school in south Iran's Lamerd: Report

At least 21 people were killed in a February 28 strike on an elementary school and adjacent sports hall in Lamerd, Iran, coinciding with a separate Tomahawk strike in Minab that reportedly killed 175. Reporting and video evidence point to the use of the newly developed US Precision Strike Missile (PrSM), which completed prototype testing last year and was confirmed by CENTCOM as used in the Iran war, though its use in Lamerd has not been explicitly confirmed by the US military. Imagery of mid-air detonation and tungsten pellet damage raise questions whether the effect was intentional, a design/manufacturing defect, or a targeting error, increasing geopolitical risk and potential market risk-off dynamics.

Analysis

This event is less about a single weapon than about immediate counterparty, regulatory, and procurement risk that concentrates on the prime contractor. Expect an acute headline-driven repricing over days as algos and discretionary funds de-risk exposure to perceived engineering or compliance failures; a 5–12% move in the prime’s stock within 2–10 trading days is plausible absent a clear exculpatory technical report. Over the next 1–6 months, Department of Defense contract reviews, expedited safety audits, and possible pauses on follow-on shipments create delivery slippage and margin pressure that can flow through quarterly guidance revisions.

Second-order winners are firms with in-service, field-proven alternatives and those that provide independent test, verification, and safety certification services; competitors with less exposure to new-system rollout risk can capture reallocated orders and aftermarket spending. Suppliers deep in the production chain (single-source avionics, guidance modules) face accelerated qualification scrutiny that could shift subcontract awards or drive dual-sourcing with 6–18 month requalification windows, creating both supply disruptions and new TAM for test/qualification vendors. Expect export-control and insurer scrutiny to harden, increasing program compliance costs and reducing the slope of international aftermarket growth over the next 12–24 months.

Key catalysts to watch: (1) an independent failure analysis released within 30–90 days that either isolates a manufacturing defect or clears design; (2) DoD statements about contract pauses or continuations in the next 2–12 weeks; (3) observable re-awarding of subsystems to competitors on 3–12 month timelines. The trade flips if a transparent forensic report convincingly attributes the incident to a discrete non-recurring manufacturing fault — that would compress the downside and potentially create a bounce of similar magnitude.

Key Decisions for Investors

• Short LMT equity (size to 1–2% of portfolio) or buy 1-month ATM puts with a 7–12% downside target and a hard stop at 6% loss; time entry in the next 1–5 trading days to capture headline-driven volatility. R/R roughly 1:2–1:3 given high near-term event risk.
• Pair trade: short LMT / long RTX (equal dollar exposure) over 3–12 months to capture potential procurement reallocation; target a 15–25% relative outperformance. Close the pair if the spread tightens by 8% or if a DoD statement confirms continuation of prime contracts.
• Long Northrop Grumman (NOC) or other proven-system primes (size 1–2%) for 6–18 months as a defensive reallocation into fielded-system exposure; target 10–20% upside if budget/award flow shifts. Monitor program-level award notices and testing-contract announcements as entry signals.
• Long small-cap test/qualification and systems-integration firms (selective, concentrated) with 6–12 month horizon — these stand to win incremental TAM from new safety/regulatory regimes. Take profits on a 25% move or if official investigations clear the incumbent within 90 days.